At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 96 enrolled
Drug / intervention
Epeleuton +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered Epeleuton In NAFLD Patients.
In Brief
A Phase 2 clinical trial evaluating Placebo capsules and Epeleuton for Non Alcoholic Fatty Liver Disease. Completed, enrolled 96 participants across 16 sites in 3 countries.
Detailed Summary
The purpose of this randomised, double-blind, placebo-controlled, parallel group study is to assess the safety and efficacy of orally administered Epeleuton capsules versus placebo in the treatment of adult patients with Non Alcoholic Fatty Liver Disease (NAFLD)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Alcoholic Fatty Liver Disease
CountriesGeorgia, Ukraine, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartDec 2016
Primary CompletionJan 2019
Study CompletionMar 2019
TodayJul 2026
First PostedOct 21, 2016
Enrollment StartDec 20, 2016
Primary CompletionJan 2, 2019
Study CompletionMar 4, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 9.7 years ago
Interventions
Placebo capsulesother
Epeleutondrug